reports
Corium, Inc. Announces FDA Filing Acceptance of New Drug Application f...
Corium, Inc. Announces FDA Filing Acceptance of New Drug Application for ADLARITY® (donepezil transdermal system) for the Treatment of Alzheimer’s Disease MENLO PARK, Calif., Jan. 27, 2020 (GLOBE NEWSWIRE) -- Corium, Inc., a commercial-stage biopharmaceutical company leading the development of novel transdermal healthcare products that are intended to provide alternative treatment options for patients and their families, today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing the company’s New Drug Application (NDA) for ADLARITY (donepezil transdermal syst...
Corium Appoints Perry Sternberg as Chief Executive Officer
Corium Appoints Perry Sternberg as Chief Executive Officer Former Shire Executive Brings Strong Track Record in Commercializing CNS Products MENLO PARK, Calif., April 02, 2019 (GLOBE NEWSWIRE) -- Corium, Inc. announced today that its Board of Directors has named Perry Sternberg as Chief Executive Officer. Mr. Sternberg is a senior pharmaceutical executive with commercial experience across a wide range of therapeutic areas in diverse markets. He most recently served a dual role at Shire Plc as the Head of U.S. Commercial for seven therapeutic area business units, as well as the Chief Co...
Corium Announces Agreement for Gurnet Point Capital to Purchase All Ou...
Corium Announces Agreement for Gurnet Point Capital to Purchase All Outstanding Shares Total Transaction Valued in Excess of $500 Million, Representing a 50% Premium Gurnet Point Capital to Expand Operations While Focusing on the Approval and Commercialization of Corium’s Corplex Donepezil MENLO PARK, Calif., Oct. 11, 2018 (GLOBE NEWSWIRE) -- Corium International, Inc. (Nasdaq: CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced that it has entered into a definitive merger ag...
Corium to Present at the 2018 Cantor Fitzgerald Global Healthcare Conf...
Corium to Present at the 2018 Cantor Fitzgerald Global Healthcare Conference MENLO PARK, Calif., Sept. 24, 2018 (GLOBE NEWSWIRE) -- Corium International, Inc. (Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced that Peter Staple, Corium’s President and Chief Executive Officer, will present at the Cantor Fitzgerald Global Healthcare Conference on Monday, October 1, 2018 at 2:20 PM EDT. A live audio webcast of Corium’s presentation may be accessed or by visiting “Event...
Corium to Present at the H. C. Wainwright 20th Annual Global Investmen...
Corium to Present at the H. C. Wainwright 20th Annual Global Investment Conference MENLO PARK, Calif., Aug. 29, 2018 (GLOBE NEWSWIRE) -- Corium International, Inc. (Nasdaq: CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced that Peter Staple, Corium’s President and Chief Executive Officer, will present at the H.C. Wainwright 20th Annual Global Investment Conference on Wednesday, September 5, 2018 at 9:35 AM EDT. A live audio webcast of Corium’s presentation may be accessed ...
Corium Reports Third Quarter Fiscal 2018 Financial Results and Corpora...
Corium Reports Third Quarter Fiscal 2018 Financial Results and Corporate Highlights MENLO PARK, Calif., Aug. 09, 2018 (GLOBE NEWSWIRE) -- Corium International, Inc. (Nasdaq: CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, today announced unaudited financial results for the third fiscal quarter and the nine months ended June 30, 2018 and reported on recent corporate developments. Corium's fiscal year ends on September 30. Corporate Highlights Corplex™ Donepezil on track for filing — Cor...
Corium to Report Third Quarter Fiscal 2018 Financial Results on Thursd...
Corium to Report Third Quarter Fiscal 2018 Financial Results on Thursday, August 9, 2018 MENLO PARK, Calif., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Corium International, Inc. (NASDAQ: CORI) today announced that it will report financial results for the third quarter ended June 30, 2018 on Thursday, August 9, 2018 after the close of the U.S. financial markets. Corium will host a conference call and live audio webcast at 5:00 p.m. Eastern time, 2:00 p.m. Pacific time to discuss its financial results and report on recent progress. Conference Call and Webcast Details: Investors and analysts can ...
Corium Presents Additional Positive Clinical Results at Alzheimer's As...
Corium Presents Additional Positive Clinical Results at Alzheimer's Association International Conference® 2018 Pharmacodynamic Results Further Support Therapeutic Equivalence of Corplex™ Donepezil to Aricept® MENLO PARK, Calif., July 25, 2018 (GLOBE NEWSWIRE) -- Corium International, Inc. (Nasdaq:CORI), a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, announced that Parminder "Bobby" Singh, Ph.D., Corium's Chief Technology Officer and Vice President, Research and Development, presented positive ...
Corium Announces Issuance of Additional U.S. Patent Covering Corplexâ„...
Corium Announces Issuance of Additional U.S. Patent Covering Corplex™ Donepezil Transdermal System for Alzheimer’s Disease Second Orange Book Listable Patent Provides Expanded Coverage to 2037 MENLO PARK, Calif., July 11, 2018 (GLOBE NEWSWIRE) -- Corium International, Inc. (NASDAQ:CORI), a commercial stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, announced today that the United States Patent and Trademark Office has issued a new key patent related to the company’s Corplex Donepezil Transdermal Delivery Sys...
Corium Announces Issuance of Key U.S. Patent Covering Corplexâ„¢ Donep...
Corium Announces Issuance of Key U.S. Patent Covering Corplex™ Donepezil Transdermal System for Alzheimer’s Disease Provides Composition of Matter Coverage to 2037 MENLO PARK, Calif., June 13, 2018 (GLOBE NEWSWIRE) -- Corium International, Inc. (NASDAQ:CORI), a commercial stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty transdermal products, announced today that the United States Patent and Trademark Office (PTO) has issued a cornerstone patent related to the company’s Corplex Donepezil Transdermal Delivery System (TDS), a once-w...
- Jonathan Moreland
KRG KITE REALTY GROUP TRUST
CG3 CELGENE CORPORATION
UFPT UFP TECHNOLOGIES
SRN SPRINT CORP.
ROX CASTLE BRANDS
EVEREST RE GROUP LTD.
PSX PHILLIPS 66
PSMT PRICESMART INC.
PRTK PARATEK PHARMACEUTICALS INC
PRCP PERCEPTRON INC.
PBH PRESTIGE CONSUMER HEALTHCARE INC
OSIS OSI SYSTEMS INC.
OPK OPKO HEALTH INC.
MOFG MIDWESTONE FINANCIAL GROUP
A2N6GQ LEGACY RESERVES
A2LQV6 KKR & CO INC
WXC1 CENTERSPACE
58I1 INTREPID POTASH INC.
HSTM HEALTHSTREAM INC.
GABC GERMAN AMERICAN BANCORP
FTAI FORTRESS TRANSPORTATION AND INFRASTRUCTURE INVESTORS LLC
FSIC FS KKR CAPITAL CORP.
DYNT DYNATRONICS
CPSS CONSUMER PORTFOLIO SERVICES INC.
CORI CORIUM INTERNATIONAL
BOCH BANK OF COMMERCE HOLDINGS
ASPS ALTISOURCE PORTFOLIO SOLUTIONS S.A.
ANCX ACCESS NATIONAL CORP.
AKAO ACHAOGEN INC.
MCBC MACATAWA BANK CORP.
SKY SKYLINE CHAMPION CORPORATION
SHLD SEARS HOLDINGS CORPORATION
ANY SPHERE 3D CORP
CCV COUNTERPATH
OW0A OCWEN FINANCIAL CORPORATION
UGI UGI CORPORATION
VSI VITAMIN SHOPPE
PCF PUTNAM HIGH INCOME SECURITIES FUND
NYNY EMPIRE RESORTS INC.
OTEL OTELCO INC
CNBKA CENTURY BANCORP INC. CL A
SBAC SBA COMMUNICATIONS CORP. CLASS A
APEN APOLLO ENDOSURGERY
AAXN AXON ENTERPRISE
KALA INC.
BCO KALA PHARMACEUTICALS INC.
TEI THE BRINK'S COMPANY
CCUR TEMPLETON EMERGING MARKETS INCOME FUND
MSF CONCURRENT COMPUTER CORPORATION
UNTY MORGAN STANLEY EMERGING MARKETS FUND INC.
MFOND UNITY BANCORP INC.
CHN MOBIVITY HOLDINGS
ARGS THE CHINA FUND
MSLP INC.
ARGOS THERAPEUTICS INC
MUSCLE PHARM CORP.
- Jonathan Moreland
VECO VEECO INSTRUMENTS INC.
SRN SPRINT CORP.
ROX CASTLE BRANDS
EVEREST RE GROUP LTD.
PSMT PRICESMART INC.
PRCP PERCEPTRON INC.
PLAY DAVE & BUSTER'S ENTERTAINMENT INC.
OPK OPKO HEALTH INC.
NMFC NEW MOUNTAIN FINANCE CORPORATION
MOFG MIDWESTONE FINANCIAL GROUP
A2N6GQ LEGACY RESERVES
WXC1 CENTERSPACE
HSTM HEALTHSTREAM INC.
GABC GERMAN AMERICAN BANCORP
FTAI FORTRESS TRANSPORTATION AND INFRASTRUCTURE INVESTORS LLC
FSIC FS KKR CAPITAL CORP.
DYNT DYNATRONICS
CPSS CONSUMER PORTFOLIO SERVICES INC.
CORI CORIUM INTERNATIONAL
CHTR CHARTER COMMUNICATIONS INC. CLASS A
BOCH BANK OF COMMERCE HOLDINGS
ASPS ALTISOURCE PORTFOLIO SOLUTIONS S.A.
ALIM ALIMERA SCIENCES
AKAO ACHAOGEN INC.
MCBC MACATAWA BANK CORP.
SKY SKYLINE CHAMPION CORPORATION
SHLD SEARS HOLDINGS CORPORATION
ANY SPHERE 3D CORP
CCV COUNTERPATH
CQP CHENIERE ENERGY PARTNERS L.P.
OW0A OCWEN FINANCIAL CORPORATION
VSI VITAMIN SHOPPE
PCF PUTNAM HIGH INCOME SECURITIES FUND
NYNY EMPIRE RESORTS INC.
SYRS SYROS PHARMACEUTICALS
CNBKA CENTURY BANCORP INC. CL A
RETA REATA PHARMACEUTICALS INC. CLASS A
SBAC SBA COMMUNICATIONS CORP. CLASS A
APEN APOLLO ENDOSURGERY
AAXN AXON ENTERPRISE
JILL INC.
WOW J.JILL INC.
KALA WIDEOPENWEST INC.
CBMG KALA PHARMACEUTICALS INC.
TEI CELLULAR BIOMEDICINE GROUP INC
MSF TEMPLETON EMERGING MARKETS INCOME FUND
STKL MORGAN STANLEY EMERGING MARKETS FUND INC.
COGT SUNOPTA
JOE INC.
UNTY FLUENT INC
MFOND ST JOE CO.
CHN UNITY BANCORP INC.
ARGS MOBIVITY HOLDINGS
THE CHINA FUND
INC.
ARGOS THERAPEUTICS INC
- Jonathan Moreland
ULTI ULTIMATE SOFTWARE GROUP INC.
BASX BASIC ENERGY SERVICES INC.
ZYNE ZYNERBA PHARMACEUTICALS
WMS ADVANCED DRAINAGE SYSTEMS INC.
SPPI SPECTRUM PHARMACEUTICALS INC.
PRCP PERCEPTRON INC.
PDVW PDVWIRELESS
MTDR MATADOR RESOURCES COMPANY
MNOV MEDICINOVA
A2N6GQ LEGACY RESERVES
LFUS LITTELFUSE INC.
HBAN HUNTINGTON BANCSHARES INCORPORATED
FITB FIFTH THIRD BANCORP
CORR CORENERGY INFRASTRUCTURE TRUST
CORI CORIUM INTERNATIONAL
CASY CASEY'S GENERAL STORES INC.
BMRC BANK OF MARIN BANCORP
BGNE BEIGENE LTD. SPONSORED ADR
ASPS ALTISOURCE PORTFOLIO SOLUTIONS S.A.
ANCX ACCESS NATIONAL CORP.
AKAO ACHAOGEN INC.
MCBC MACATAWA BANK CORP.
SKY SKYLINE CHAMPION CORPORATION
RVLT REVOLUTION LIGHTING TECHNOLOGIES
SHLD SEARS HOLDINGS CORPORATION
BMRA BIOMERICA INC.
CCV COUNTERPATH
CQP CHENIERE ENERGY PARTNERS L.P.
PCF PUTNAM HIGH INCOME SECURITIES FUND
NYNY EMPIRE RESORTS INC.
KINS KINGSTONE COS. INC.
TWLO TWILIO INC. CLASS A
WINA WINMARK CORP.
ALBO ALBIREO PHARMA
SBAC SBA COMMUNICATIONS CORP. CLASS A
APEN APOLLO ENDOSURGERY
PKTX PROTOKINETIX INC
KALA KALA PHARMACEUTICALS INC.
MBOT MICROBOT MEDICAL
RFIL RF INDUSTRIES LTD.
TEI TEMPLETON EMERGING MARKETS INCOME FUND
MSF MORGAN STANLEY EMERGING MARKETS FUND INC.
UNTY UNITY BANCORP INC.
ESQ ESQUIRE FINANCIAL HOLDINGS
TDF TEMPLETON DRAGON FUND INC.
CHN THE CHINA FUND
INC.
- Jonathan Moreland
BASX BASIC ENERGY SERVICES INC.
SHAK SHAKE SHACK INC. CLASS A
VECO VEECO INSTRUMENTS INC.
UAN CVR PARTNERS LP
SRN SPRINT CORP.
ROX CASTLE BRANDS
EVEREST RE GROUP LTD.
PSMT PRICESMART INC.
PRGX PRGX GLOBAL
PRCP PERCEPTRON INC.
PLAY DAVE & BUSTER'S ENTERTAINMENT INC.
OPK OPKO HEALTH INC.
NMFC NEW MOUNTAIN FINANCE CORPORATION
MNOV MEDICINOVA
MELI MERCADOLIBRE INC.
A2N6GQ LEGACY RESERVES
WXC1 CENTERSPACE
HSTM HEALTHSTREAM INC.
GPRO GOPRO INC. CLASS A
GABC GERMAN AMERICAN BANCORP
FTAI FORTRESS TRANSPORTATION AND INFRASTRUCTURE INVESTORS LLC
FSIC FS KKR CAPITAL CORP.
DYNT DYNATRONICS
DISCA DISCOVERY INC. CLASS A
CORI CORIUM INTERNATIONAL
CHTR CHARTER COMMUNICATIONS INC. CLASS A
BKMU BANK MUTUAL CORP.
ASPS ALTISOURCE PORTFOLIO SOLUTIONS S.A.
ASB ASSOCIATED BANC-CORP
AKAO ACHAOGEN INC.
MCBC MACATAWA BANK CORP.
SKY SKYLINE CHAMPION CORPORATION
CCV COUNTERPATH
CQP CHENIERE ENERGY PARTNERS L.P.
FI FRANK'S INTERNATIONAL NV
OW0A OCWEN FINANCIAL CORPORATION
VSI VITAMIN SHOPPE
PCF PUTNAM HIGH INCOME SECURITIES FUND
NYNY EMPIRE RESORTS INC.
SYRS SYROS PHARMACEUTICALS
CNBKA CENTURY BANCORP INC. CL A
RETA REATA PHARMACEUTICALS INC. CLASS A
SBAC SBA COMMUNICATIONS CORP. CLASS A
APEN APOLLO ENDOSURGERY
AAXN AXON ENTERPRISE
JILL INC.
WOW J.JILL INC.
KALA WIDEOPENWEST INC.
CBMG KALA PHARMACEUTICALS INC.
TEI CELLULAR BIOMEDICINE GROUP INC
MSF TEMPLETON EMERGING MARKETS INCOME FUND
STKL MORGAN STANLEY EMERGING MARKETS FUND INC.
COGT SUNOPTA
JOE INC.
FLUENT INC
ST JOE CO.
QuickView: Redefining the possibilities of drug patches
Corium is a specialty pharmaceutical company focused on the development of advanced transdermal drug delivery technology. The company receives revenue from three partnered products (including Crest Whitestrips) and is now developing products internally. It has two platforms (Corplex and MicroCor) that enable the formulation of poorly soluble drugs and biologics respectively, both of which were previously intractable. There is the potential for four 505(b)2 approvals in 2019-21.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.